Amendments to the Claims

1. (Cancelled)

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Cancelled)

7. (Cancelled)

8. (Currently Amended) A compound selected from the group consisting of:

3-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

4-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

4-{3-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,

4-{4-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,

4-(2-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-ethyl)-benzamide,

2-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

3-{3-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

3-(4-{[(Methyl-(3-methyl-butyl)-amino]-methyl}-phenoxymethyl)-benzamide,

3-{4-[(3,3-Dimethyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

3-(4-{[2-(Tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxymethyl)-benzamide,

3-(4-{[2-(4-Fluoro-phenyl)-ethylamino]-methyl}-phenoxymethyl)-benzamide,

3-{3-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,

3-{4-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,

4-{3-[2-(3-Methyl-butylamino)-ethyl]-benzyloxy}-benzamide,

3-[4-(2-Benzylamino-ethyl)-Phenoxymethyl]-benzamide, or a pharmaceutically acceptable salt~~, solvate, enantiomer, diastereomer and diastereomeric mixture~~or solvate thereof.

9. (Currently Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of ~~Claim 1~~Claim 8 in association with a carrier, diluent and/or excipient.

10. (Cancelled)

11.   (Cancelled)

12.   (Cancelled)

13.   (Cancelled)

14.   (Cancelled)

15.   (Cancelled)

16.   (New) A compound selected from the group consisting of

3-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

4-{4-[(3-Methyl-butylamino)-methyl]-phenoxymethyl}-benzamide,

4-{3-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,

4-{4-[(3-Methyl-butylamino)-methyl]-benzyloxy}-benzamide,

4-(2-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-ethyl)-benzamide, or a pharmaceutically

acceptable salt or solvate thereof.